Medeor Therapeutics, Inc.
https://medeortx.com/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medeor Therapeutics, Inc.
Regenerative Medicine Comes Of Age – In The Age Of COVID-19
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
Pipeline Watch: Phase III Starts For Molidustat, Tecentriq And Tislelizumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Venture Funding Deals: Semma, Arcus Raise $100m-Plus For Cancer, Diabetes Therapies
Semma's $114m Series B round and a $107m Series C for Arcus top November's list of biopharmaceutical venture capital deals. Forty Seven, Medeor and Tricida also closed sizeable rounds.
Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice